Dubey Ankur Rakesh, Mishra Ribhav, Jagtap Yuvraj Anandrao, Kinger Sumit, Kumar Prashant, Dhiman Rohan, Ghosh Somnath, Singh Sarika, Prasad Amit, Jana Nihar Ranjan, Mishra Amit
Cellular and Molecular Neurobiology Unit, Indian Institute of Technology Jodhpur, Jodhpur, 342037, Rajasthan, India.
Laboratory of Mycobacterial Immunology, Department of Life Science, National Institute of Technology, Rourkela, Odisha, 769008, India.
Mol Neurobiol. 2023 May;60(5):2397-2412. doi: 10.1007/s12035-023-03230-0. Epub 2023 Jan 19.
Cells perform regular maintenance to avoid the accumulation of misfolded proteins. Prolonged accumulation of these proteotoxic inclusions generates potential risk of ageing-related diseases such as neurodegenerative diseases. Therefore, removal of such abnormal aggregates can ensure the re-establishment of proteostasis. Ubiquitin proteasome system (UPS) actively participates in the selective removal of aberrantly folded clients with the help of complex proteasome machinery. However, specific induction of proteasome functions to remove abnormal proteins remains an open challenge. Here, we show that Itraconazole treatment induces proteasome activities and degrades the accumulation of bonafide-misfolded proteins, including heat-denatured luciferase. Exposure of Itraconazole elevates the degradation of neurodegenerative disease-associated proteins, e.g. expanded polyglutamine, mutant SOD1, and mutant α-synuclein. Our results suggest that Itraconazole treatment prevents the accumulation of neurodegenerative disease-linked misfolded proteins and generates cytoprotection. These findings reveal that Itraconazole removes abnormal proteins through sequential proteasomal activation and represents a potential protective therapeutic role against protein-misfolding neurodegenerative diseases.
细胞进行定期维护以避免错误折叠蛋白质的积累。这些蛋白毒性内含物的长期积累会产生与衰老相关疾病(如神经退行性疾病)的潜在风险。因此,清除此类异常聚集体可确保蛋白质稳态的重新建立。泛素蛋白酶体系统(UPS)借助复杂的蛋白酶体机制积极参与选择性清除异常折叠的底物。然而,特异性诱导蛋白酶体功能以清除异常蛋白质仍然是一个有待解决的挑战。在此,我们表明伊曲康唑处理可诱导蛋白酶体活性并降解真正错误折叠的蛋白质(包括热变性荧光素酶)的积累。伊曲康唑的暴露提高了与神经退行性疾病相关蛋白质(如扩展的聚谷氨酰胺、突变型SOD1和突变型α-突触核蛋白)的降解。我们的结果表明,伊曲康唑处理可防止与神经退行性疾病相关的错误折叠蛋白质的积累并产生细胞保护作用。这些发现揭示,伊曲康唑通过顺序性蛋白酶体激活来清除异常蛋白质,并代表了对蛋白质错误折叠神经退行性疾病的潜在保护治疗作用。